Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part III (unsolved questions & subsequent case law)

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ أكثر حفظ في قائمتي
  • المؤلفون: Minssen, Timo; Nilsson, David
  • المصدر:
    Minssen , T & Nilsson , D 2012 , ' Standing on shaky ground- US patent-eligibility of isolated DNA and genetic diagnostics after AMP v. USPTO - Part III (unsolved questions & subsequent case law) ' , Queen Mary Journal of Intellectual Property , vol. 2 , no. 3 , pp. 225-249 . <
  • نوع التسجيلة:
    Electronic Resource
  • الدخول الالكتروني :
    https://researchprofiles.ku.dk/da/publications/standing-on-shaky-ground-us-patenteligibility-of-isolated-dna-and-genetic-diagnostics-after-amp-v-uspto--part-iii-unsolved-questions--subsequent-case-law(f90b21d4-2910-4e4b-9dc4-55129d2eb462).html
    http://www.e-elgar.com/journals/journal_main.lasso?ref=QMJIP
  • معلومة اضافية
    • Publisher Information:
      2012
    • نبذة مختصرة :
      This is the third part of a four-partite article discussing the US Federal Circuit decision in AMP v. USPTO , also known as the ACLU /Myriad "gene patenting" case ("Myriad"). Part I commenced with a description of the legal framework and an explanation of how the decision relates to the recently invigorated U.S. debate on patent eligibility, referring inter alia to the 2010 U.S. Supreme Court decision in Bilski v. Kappos and the pending certiorari in Prometheus v. Mayo (1). Before this background, Part I recited the complex procedural history of AMP v. USPTO (2) and summarized the underpinnings of the outcome, i.e. the three different opinions of the Federal Circuit judges Lourie, Moore & Bryson who comprised the panel (3). Part II continued the tale with a detailed analysis of the decision's practical implications (4), which is followed by a closer look on the chances for an ultimate Supreme Court review (5). Why a potential Supreme Court review of AMP v. USPTO would indeed be a much welcomed and necessary development is now analyzed in Part III. This part will elaborate on the myriad of unsolved questions raised by both AMP v. USPTO and a bulk of subsequent case law addressing the patent-eligibility of biological correlations and software-related "inventions" (6). These subsequent decisions indicate a serious split at the Federal Circuit with potentially broad implications not only for the patent eligibility of software-related patent applications and so-called "Beauregard"- claims, but also for biotech-claims directed to personalized medicine, biological correlations and compounds containing biological information. As far as possible, this part also incorporates new developments that can be expected in the coming months, such as the pending certiorari decision in AMP v. USPTO and the pending Supreme Court decision in Prometheus v. Mayo. Part IV, which is to be published in issue 4, will finally offer a broader discussion of the recent US patent-eligibility de
    • الموضوع:
      dk/atira/pure/core/keywords/TheFacultyOfLaw; Faculty of Law; Patents, personalized medicine, DNA, diagnostic methods; article
    • Availability:
      Open access content. Open access content
      info:eu-repo/semantics/restrictedAccess
    • Note:
      English
    • Other Numbers:
      DAV oai:pure.atira.dk:publications/f90b21d4-2910-4e4b-9dc4-55129d2eb462
      1322615361
    • Contributing Source:
      UNIV OF COPENHAGEN
      From OAIster®, provided by the OCLC Cooperative.
    • الرقم المعرف:
      edsoai.on1322615361
HoldingsOnline